Nebivolol Teva (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Teva, is a beta blocker presented as an oral tablet for oral use. It selectively reduces elevated blood pressure and improves cardiovascular outcomes in adult patients with hypertension.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets while adhering to stringent Good Distribution Practice standards and providing comprehensive support for product registration and logistics.

Nebivolol is a beta‑adrenergic blocker used primarily in the management of hypertension.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events in adult patients. - Essential hypertension: provides sustained blood‑pressure control in patients with primary (essential) hypertension. - Secondary hypertension: can be employed as part of therapy for hypertension secondary to other medical conditions when appropriate.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache reported in several patients. - Dizziness: transient light‑headedness, especially after initial dosing. - Fatigue: feeling of tiredness or reduced energy. - Nausea: occasional upset stomach or queasiness. - Nasal congestion: mild blockage of nasal passages. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate that may require medical attention. - Heart block: impairment of electrical conduction in the heart. - Bronchospasm: narrowing of airways, particularly in patients with reactive airway disease. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling indicating hypersensitivity. - Hypotension: significant drop in blood pressure causing faintness or shock.

Before initiating therapy, clinicians should consider several safety factors.

- Blood pressure monitoring: regularly assess to ensure therapeutic targets are met. - Cardiac function evaluation: evaluate heart rate and rhythm, especially in patients with existing conduction disorders. - Respiratory caution: use carefully in patients with asthma or chronic obstructive pulmonary disease. - Renal/hepatic impairment: dose may need adjustment in moderate to severe organ dysfunction. - Discontinuation: avoid abrupt cessation; taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: concurrent use may cause excessive bradycardia or hypotension. - Non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem): can markedly depress cardiac conduction. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring blood‑pressure monitoring. - ACE inhibitors or ARBs: combined therapy can lead to additive blood‑pressure lowering. - NSAIDs: may attenuate antihypertensive response. - Anti‑arrhythmic agents: may affect cardiac rhythm when used together. - Antidiabetic drugs: nebivolol can mask hypoglycaemia symptoms; monitor glucose levels.